

23 August 2018

Resonance Health announces two new clinical trial contracts

Resonance Health Limited (ASX: RHT) (“Resonance Health” or the “Company”) is pleased to announce that the Company has executed two separate multi-year contracts with pharmaceutical and therapeutic companies for the use of Ferriscan® and other Resonance Health products and services.

The total dollar value for the two contracts is approximately US\$522,000. Payments will be made throughout the duration of the clinical trials. Full payment for each trial is subject to the successful completion of each clinical trial.

This announcement brings the total amount of clinical trial work won in the 2018 calendar year to a combined aggregate total of approximately US\$1,418,000. FerriScan and other Resonance Health services are now being used by seven pharmaceutical and therapeutic companies in a total of eight clinical trials.

Resonance Health continues to actively pursue additional clinical trial opportunities with pharmaceutical companies as the Company looks to further utilise its capabilities to provide Contract Research Organisation (CRO) services.

The Company also announces that the application for regulatory clearance for FerriSmart® (Artificial Intelligence tool for the quantification of liver iron concentration) was recently submitted to the FDA.

Further updates will be provided as work progresses.

Alison Laws

Chief Executive Officer

For further information please contact:

Chad Tondut

Communications Manager, Resonance Health

E: chadt@resonancehealth.com P: +61 (0)8 9286 5300